<?xml version="1.0" encoding="UTF-8"?>
<p id="p0115">Set in the context of the Ebola outbreak that began in 2014, multiple stakeholders were mobilised to respond to the humanitarian crisis of this escalating outbreak. Although there was no licenced Ebola vaccine available, approximately fifteen different vaccines were in preclinical development, including DNA vaccines, virus-like particles and viral vector 
 <xref rid="b0015" ref-type="bibr">[3]</xref>. Levine et al. 
 <xref rid="b0020" ref-type="bibr">[4]</xref> described how these candidates had largely been developed as part of the bioterrorism preparedness programme, BioShield, in the United States. Due to the relatively low geographic prevalence of infection there was a limited market and thus a poor case for industry to develop a vaccine for commercial purposes. However, concerns over the potential use of Ebolavirus as a bioterrorism agent resulted in a number of stockpiled sources that had undergone testing in animal models 
 <xref rid="b0020" ref-type="bibr">[4]</xref>.
</p>
